BACKGROUND AND PURPOSE: We sought to identify variables associated with @entity1779 in @entity1 with acute @entity385 who receive @entity3479 ). METHODS: We performed subgroup analyses of data from a randomized, double-blind, placebo-controlled trial of intravenous @entity3479 administered to @entity64 @entity1 within 3 hours of onset. Using multivariable regression modeling procedures, we assessed the relationship of baseline and after-treatment variables with symptomatic and asymptomatic @entity1779 during the first 36 hours after treatment. RESULTS: Overall, @entity3479 -treated @entity1 had an increase in the absolute risk of symptomatic @entity1779 of 6% and a decrease in the absolute risk of 3-month mortality of 4% compared with placebo-treated @entity1 . The only variables independently associated with an increased risk of symptomatic @entity1779 in the final multivariable logistic regression model for the 312 @entity3479 -treated @entity1 were the severity of @entity51 as measured by the National Institutes of Health @entity64 Scale score (five categories; odds ratio [OR], 1.8; 95% confidence interval [CI], 1.2 to 2.9) and @entity2657 (defined as acute @entity6152 ) or mass effect by CT before treatment (OR, 7.8; 95% CI, 2.2 to 27.1). This final model correctly predicted those @entity3479 -treated @entity1 who would or would not have a symptomatic @entity548 with only 57% efficiency. In the subgroup of @entity1 with a severe @entity51 , @entity3479 -treated @entity1 were more likely than placebo-treated @entity1 to have a favorable 3-month outcome (adjusted OR based on multiple outcomes, 4.3; 95% CI, 1.6 to 11.9). These results were similar for the subgroup with @entity4 or mass effect by CT (adjusted OR, 3.4; 95% CI, 0.6 to 20.7). The likelihood of severe disability or death was similar for @entity3479 - and placebo-treated @entity1 with these two baseline characteristics. CONCLUSIONS: Despite a higher rate of @entity1779 , @entity1 with severe @entity64 or @entity4 or mass effect on the baseline-CT are reasonable candidates for @entity3479 , if it is administered within 3 hours of onset.

@entity1779 after intravenous @entity3479 therapy for XXXX . The NINDS @entity3479 @entity64 Study Group.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity64 :: ('MESH:D020521', 'Disease') :: ['strokes', 'stroke', 'Stroke'] @entity2657 :: ('MESH:D001929', 'Disease') :: ['brain edema'] @entity6152 :: ('MESH:C565408', 'Disease') :: ['hypodensity'] @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage'] @entity4 :: ('MESH:D004487', 'Disease') :: ['edema'] @entity51 :: ('MESH:D009461', 'Disease') :: ['neurological deficit'] @entity3479 :: ('5327', 'Gene') :: ['tissue plasminogen activator (t-PA', 't-PA'] @entity1779 :: ('MESH:D002543', 'Disease') :: ['intracerebral hemorrhage'] @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']
@entity385 :: (MESH:D002544,Disease) :: ['ischemic stroke']
